These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33307889)

  • 41. Drug resistance profile of Mycobacterium tuberculosis and predictors associated with the development of drug resistance.
    Hameed S; Ahmad SR; Rahman MAU; Nazir H; Ullah I
    J Glob Antimicrob Resist; 2019 Sep; 18():155-159. PubMed ID: 30910744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients.
    Gomathi NS; Singh M; Myneedu VP; Chauhan DS; Tripathy S; Sarin R; Mohan A; Bhatnagar A; Khangembam JS; Kannan T; V Rao MV; Logani J; Dey B; Gangakhedkar RR; Swaminathan S; Singh UB
    Indian J Med Res; 2020 Nov; 152(5):482-489. PubMed ID: 33707390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India.
    Shewade HD; Kokane AM; Singh AR; Verma M; Parmar M; Chauhan A; Chahar SS; Tiwari M; Khan SN; Gupta V; Tripathy JP; Nagar M; Singh SK; Mehra PK; Kumar AM
    BMC Health Serv Res; 2017 Apr; 17(1):249. PubMed ID: 28376789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determinants of drug resistant & drug sensitive tuberculosis patients from North India-a case control study.
    Goel S; Thakur D; Singh A
    Indian J Tuberc; 2021; 68S():S108-S114. PubMed ID: 34538384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape.
    Monedero-Recuero I; Gegia M; Wares DF; Chadha SS; Mirzayev F
    Int J Infect Dis; 2021 Jul; 108():557-567. PubMed ID: 34139370
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multidrug-resistant tuberculosis surveillance and cascade of care in Madagascar: a five-year (2012-2017) retrospective study.
    Knoblauch AM; Grandjean Lapierre S; Randriamanana D; Raherison MS; Rakotoson A; Raholijaona BS; Ravaoarimanga M; Ravololonandriana PE; Rabodoarivelo MS; Ratsirahonana O; Rakotomanana F; Razafindranaivo T; Rasolofo V; Rakotosamimanana N
    BMC Med; 2020 Jun; 18(1):173. PubMed ID: 32600414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.
    Dzeyie KA; Basu S; Dikid T; Bhatnagar AK; Chauhan LS; Narain JP
    Indian J Tuberc; 2019 Jul; 66(3):331-336. PubMed ID: 31439176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.
    Mehta S; Das M; Laxmeshwar C; Jonckheere S; Thi SS; Isaakidis P
    PLoS One; 2016; 11(9):e0162138. PubMed ID: 27611434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.
    Sachdeva KS; Raizada N; Sreenivas A; Van't Hoog AH; van den Hof S; Dewan PK; Thakur R; Gupta RS; Kulsange S; Vadera B; Babre A; Gray C; Parmar M; Ghedia M; Ramachandran R; Alavadi U; Arinaminpathy N; Denkinger C; Boehme C; Paramasivan CN
    PLoS One; 2015; 10(5):e0126065. PubMed ID: 25996389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-drug resistant tuberculosis burden and risk factors: an update.
    Marahatta SB
    Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
    J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications.
    Husain AA; Kupz A; Kashyap RS
    Epidemiol Health; 2021; 43():e2021022. PubMed ID: 33831293
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile and response to anti-tuberculosis treatment among elderly tuberculosis patients treated under the TB Control programme in South India.
    Velayutham BR; Nair D; Chandrasekaran V; Raman B; Sekar G; Watson B; Charles N; Malaisamy M; Thomas A; Swaminathan S
    PLoS One; 2014; 9(3):e88045. PubMed ID: 24618888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.
    Dorjee K; Sadutshang TD; Rana RS; Topgyal S; Phunkyi D; Choetso T; Chodon T; Parmar M; Singla R; Paster Z; Chaisson RE; Kaushal KC
    Indian J Tuberc; 2020 Jan; 67(1):59-64. PubMed ID: 32192619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008.
    Lam E; Nateniyom S; Whitehead S; Anuwatnonthakate A; Monkongdee P; Kanphukiew A; Inyaphong J; Sitti W; Chiengsorn N; Moolphate S; Kavinum S; Suriyon N; Limsomboon P; Danyutapolchai J; Sinthuwattanawibool C; Podewils LJ
    Emerg Infect Dis; 2014 Mar; 20(3):400-8. PubMed ID: 24565738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic mutations associated with rifampicin and isoniazid resistance in MDR-TB patients in North-West India.
    Kumar P; Kumar P; Balooni V; Singh S
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):434-9. PubMed ID: 25859999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.
    Tsang CA; Shah N; Armstrong LR; Marks SM
    Clin Infect Dis; 2020 Feb; 70(5):907-916. PubMed ID: 30944927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.